论文部分内容阅读
目的 评价肠内营养低聚果糖 (FOS)配方在恶性肿瘤患儿中的应用价值和前生物效应。方法 1999年 7月至 2 0 0 1年 2月 ,6 6例 2～ 12岁恶性肿瘤患儿分FOS组 (32例 )和Non FOS组 (34例 )进行前瞻性、随机、双盲对照的临床试验。患儿均按标准方案接受化疗并用NutrenJuniorFOS或NutrenJunior进行 30d的肠内营养支持。分别测定营养支持后第 13d及 30d的身高、体重、血清白蛋白(ALB)和前白蛋白 (PA)等营养指标 ;C反应蛋白 (CRP)、肿瘤坏死因子 (TNF)等免疫指标 ,并计算预期感染营养指数 ;同时测定粪便中双歧杆菌、乳酸杆菌、肠杆菌及产气荚膜梭菌含量。结果 两组治疗期间营养和免疫指标的变化无显著差异。但预期感染及营养指数 (PINI)D30时FOS组降低更加明显(P =0 .0 16 )。粪便中双歧杆菌含量在FOS组逐步上升 ,高于Non FOS组。FOS组乳酸杆菌含量上升 ,Non FOS组变化不明显。结论 肠内营养含FOS营养配方可提高抗感染能力、促进肠道正常菌群生长 ,提示其可能具有前生物效应。
Objective To evaluate the value and prebiotic effect of enteral nutrition oligofructose (FOS) formula in children with malignant tumor. Methods From July 1999 to February 2001, 66 children with malignancies aged 2 to 12 years were prospectively randomized, double-blind controlled (FOS group, 32 cases) and Non FOS group (34 cases) Clinical Trials. Children received chemotherapy according to standard protocols and enteral nutrition support with NutrenJuniorFOS or NutrenJunior for 30 days. The nutritional indexes such as height, body weight, serum albumin (ALB) and prealbumin (PA), and CRP and TNF were measured at 13 and 30 days after nutrition support, respectively. Expected nutritional index infection; simultaneous determination of fecal Bifidobacteria, Lactobacilli, Enterobacter and Clostridium perfringens content. Results There was no significant difference in the changes of nutrition and immune indexes between the two groups during the treatment. However, it was expected that the FOS group had a significantly lower infection and nutritional index (PINI) D30 (P = .016). Fecal bifidobacteria in FOS group gradually increased, higher than Non FOS group. FOS group Lactobacilli increased, Non FOS group did not change significantly. Conclusion Enteral nutrition containing FOS nutrition formula can improve anti-infective ability and promote normal intestinal flora growth, suggesting that it may have a pre-biological effects.